ZBIO
HealthcareZenas BioPharma, Inc. · Biotechnology · $850M
What is Zenas BioPharma, Inc.?
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for serious autoimmune and inflammatory diseases. Headquartered in Waltham, Massachusetts, the company is building a pipeline centered on novel antibody and fusion protein candidates.
Zenas BioPharma advances a portfolio of investigational biologics targeting autoimmune conditions. Its lead candidate, obexelimab, is a bifunctional monoclonal antibody being evaluated across multiple indications including IgG4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company generates no product revenue at this stage — it funds operations through capital raises while progressing candidates through clinical trials toward potential regulatory approval and commercialization.
Zenas BioPharma was incorporated in 2019 and is based in Waltham, Massachusetts.
- Obexelimab — bifunctional monoclonal antibody for autoimmune indications
- ZB002 — anti-TNFa monoclonal antibody candidate
- ZB004 — CTLA4-immunoglobulin fusion protein candidate
- ZB001 — anti-IGF-1R monoclonal antibody candidate
- ZB005 — anti-active complement component 1s monoclonal antibody
Is ZBIO a Good Stock to Buy?
UQS Score rates ZBIO as Poor overall, reflecting the early-stage nature of the business and the significant uncertainties that come with a pre-revenue clinical pipeline.
The Growth and Risk pillars stand out as relative bright spots within an otherwise challenging profile. The pipeline breadth across multiple autoimmune indications provides optionality, and the Risk pillar suggests the company's near-term financial structure is not among the most precarious in the clinical-stage space.
The Quality and Moat pillars are both rated Weak, consistent with a company that has no approved products, no recurring revenue, and limited durable competitive advantages established to date. Valuation is rated Elevated, meaning the current market price may already reflect optimistic pipeline assumptions.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ZBIO pay dividends?
No — Zenas BioPharma, Inc. does not currently pay a dividend.
ZBIO does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. Available capital is directed toward funding clinical trials, research operations, and pipeline advancement rather than shareholder distributions. Investors in this space generally seek returns through potential pipeline milestones and eventual commercialization rather than income.
When does ZBIO report earnings?
Zenas BioPharma reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and pipeline progress rather than traditional revenue or profit metrics. Key updates typically center on clinical trial milestones and financing activities.
For the most recent quarter's results and pipeline updates, visit Zenas BioPharma's investor relations page directly.
ZBIO Price History
+20.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Zenas BioPharma, Inc.?
Based on Zenas BioPharma, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ZBIO Long-term Outlook
The Growth pillar rating of Good reflects the potential scale of the autoimmune market and the breadth of indications being pursued across the pipeline. However, clinical-stage companies face binary outcomes at each trial readout, and the Elevated Valuation pillar suggests the market may already be pricing in favorable scenarios. The Risk pillar rated Good provides some reassurance about near-term financial stability, but pre-revenue biotechs remain inherently high-risk investments.
Growth drivers
- Obexelimab clinical progression across multiple high-unmet-need autoimmune indications
- Expanding pipeline with several distinct antibody and fusion protein candidates
- Large addressable markets in immunology, including lupus and multiple sclerosis
Key risks
- Clinical trial failure risk across any or all pipeline candidates
- Elevated valuation leaves limited margin of safety if trial results disappoint
- Ongoing capital requirements typical of pre-revenue biopharmaceutical development
ZBIO vs Peers
Zenas BioPharma operates in a competitive clinical-stage immunology landscape alongside several other development-stage and specialty biopharmaceutical companies.
Omeros focuses on inflammation and CNS disorders with a more advanced commercial and clinical history compared to Zenas's earlier-stage pipeline.
Fortrea operates as a contract research organization, supporting clinical trials across the industry rather than developing its own therapeutic pipeline.
Janux is a clinical-stage company developing T-cell engager therapies primarily in oncology, representing a different therapeutic focus than Zenas's immunology emphasis.
Frequently Asked Questions
What does Zenas BioPharma do?
Zenas BioPharma is a clinical-stage biopharmaceutical company developing immunology-based therapies for autoimmune diseases. Its pipeline includes obexelimab and several other antibody candidates targeting conditions such as lupus, multiple sclerosis, and IgG4-related disease. The company has no approved products and is currently in the clinical development phase.
Does ZBIO pay dividends?
ZBIO does not pay a dividend. Clinical-stage biopharmaceutical companies typically reinvest all available capital into research and clinical operations. Investors in ZBIO are generally seeking returns tied to pipeline progress rather than income distributions.
When does ZBIO report earnings?
Zenas BioPharma reports on a quarterly cadence standard for US-listed companies. As a pre-revenue company, reports focus on operating expenses, cash position, and pipeline milestones. Check Zenas BioPharma's investor relations page for the most current schedule and recent filings.
Is ZBIO a good stock to buy?
UQS Score rates ZBIO as Poor overall, driven by Weak Quality and Moat pillars alongside an Elevated Valuation. The Growth and Risk pillars offer relative positives, but the overall profile reflects the high uncertainty inherent in clinical-stage biopharmaceutical investing. The full pillar breakdown is available to UQS Pro members.
Is ZBIO overvalued?
The UQS Valuation pillar for ZBIO is rated Elevated, suggesting the current market price may already reflect optimistic assumptions about pipeline outcomes. For a pre-revenue company, valuation is heavily driven by clinical trial expectations rather than current financial performance. Pro members can view the detailed valuation metrics.
How does ZBIO compare to its competitors?
Compared to peers like Omeros and Janux Therapeutics, Zenas BioPharma is at an early stage with a pipeline concentrated in autoimmune immunology. Fortrea operates as a CRO rather than a drug developer. Each company carries a distinct risk and opportunity profile depending on pipeline stage and therapeutic focus.
What is ZBIO's market cap bracket?
ZBIO is classified as a small-cap stock. This is typical for clinical-stage biopharmaceutical companies that have not yet generated product revenue. Small-cap biotech stocks often carry higher volatility relative to larger, more established pharmaceutical companies.
Who founded Zenas BioPharma?
Zenas BioPharma was incorporated in 2019 and was formerly known as Zenas BioPharma (Cayman) Limited before changing its name in August 2023. Detailed founding information, including leadership history, is publicly available through the company's filings and investor relations materials.
Is ZBIO a long-term quality investment?
As a long-term quality indicator, the UQS Score rates ZBIO as Poor, reflecting weak fundamentals in Quality and Moat alongside an Elevated Valuation. Long-term quality investing typically favors companies with durable competitive advantages and consistent financial performance — characteristics that clinical-stage biotechs have yet to establish. Pro members can explore the full analysis.
What is the main competitive advantage of Zenas BioPharma?
Zenas BioPharma's potential differentiation lies in its bifunctional antibody approach with obexelimab and the breadth of autoimmune indications it is pursuing. However, the UQS Moat pillar is rated Weak, reflecting that durable competitive advantages are difficult to establish before a company has approved products generating real-world outcomes data.
What sector does ZBIO belong to?
ZBIO belongs to the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Companies in this segment are characterized by high research spending, binary clinical trial outcomes, and long development timelines before potential commercialization. You can explore more Healthcare sector stocks on UQS Score.
Is ZBIO a growth stock or value stock?
Based on UQS pillar labels, ZBIO carries a Good Growth rating — reflecting pipeline optionality across multiple indications — but an Elevated Valuation rating. This combination suggests the market is already pricing in growth expectations, leaving less room for error if clinical milestones are delayed or missed.
Unlock Full ZBIO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare ZBIO against peers in the Healthcare sector
- ✓Track pipeline-stage quality indicators over time
- ✓Get the full analyst-style view available to Pro members
Pro Analysis
ZBIO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 25.3 | 1.3 | 14.0 | 61.5 | 61.5 | 0.0 | -1.9 |
| Apr 22, 2026 | 27.2 | 1.3 | 14.0 | 61.5 | 73.6 | 0.0 | -3.0 |
| Apr 2, 2026 | 30.2 | 1.3 | 14.0 | 76.9 | 73.6 | 0.0 | — |
ZBIO — Pillar Breakdown
Quality
— 1.3/100 (25%)Zenas BioPharma, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 61.5/100 (20%)Zenas BioPharma, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 61.5/100 (15%)Zenas BioPharma, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Zenas BioPharma, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 14/100 (25%)Zenas BioPharma, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ZBIO.
Score Composition
Financial Data
More Stock Analysis
How is the ZBIO UQS Score Calculated?
The UQS (Unified Quality Score) for Zenas BioPharma, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Zenas BioPharma, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Zenas BioPharma, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.